Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 4/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | GLI1 | P08151 | 1/20 | 0.50 |
| ▸ | GLI2 | P10070 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21090366 | 0.91 | FDFT1 (0.47) | FDFT1IDO1GLI1GLI2NQO2 | |
| SCHEMBL6203942 | 0.90 | FDFT1 (0.47) | FDFT1IDO1GLI1GLI2AKR1C3 | |
| SCHEMBL13886599 | 0.88 | EPHX2 (0.59) | IDO1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL67569 | 0.88 | CYP2D6 (0.58) | IDO1NQO2LTA4HPLA2G2A | |
| SCHEMBL31506266 | 0.88 | CYP2D6 (0.58) | IDO1NQO2LTA4HPLA2G2A | |
| SCHEMBL21090363 | 0.87 | CYP4F2 (0.49) | FDFT1AKR1C3NQO2 | |
| SCHEMBL6204579 | 0.87 | MTNR1A (0.58) | — | |
| SCHEMBL6202190 | 0.85 | PLAAT3 (0.48) | FDFT1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL6204512 | 0.85 | FDFT1 (0.43) | FDFT1IDO1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL572740 | 0.85 | IDO1 (0.60) | IDO1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | FDFT1 2366/4885IDO1 86/4885GLI1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.